HEAL WELL. AGE WELL. LIVE LONGER.(800) 266-7207   ·   contact@clearhealthpass.com
Industry perspective

Peptides at a policy crossroads.

A new draft enforcement-discretion policy notice adds context to the peptide conversation.

Illustrative image for Peptide policy
Federal Register / HHS / October 30, 2026

The Federal Register published notice of the availability of a draft HHS enforcement-discretion policy concerning 503A compounding using certain peptide bulk substances. A draft policy notice does not establish that CHP has launched a program, received authorization, or demonstrated a clinical benefit.

A question to take with you.

What does the exact policy say about the substance, setting and conditions involved? Read the primary document before drawing a conclusion.

Read the primary source ↗

An editorial summary, not independent medical or investment advice. External source content is not a statement of CHP’s operational status.

Back to news & perspectives↗